{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:39Z","timestamp":1791300519683,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vph.2015.03.014","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T19:42:41Z","timestamp":1428781361000},"page":"93-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: Role of reduced oxidative stress"],"prefix":"10.1016","volume":"71","author":[{"given":"Ygal","family":"Benhamou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najah","family":"Harouki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Drouot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Zahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thuillez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robinson","family":"Joannides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2015.03.014_bb0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.014_bb0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/art.21549","volume":"54","author":"L\u00f3pez-Pedrera","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vph.2015.03.014_bb0015","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0961203308096662","article-title":"Tissue factor in the antiphospholipid syndrome","volume":"17","author":"Kinev","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.vph.2015.03.014_bb0020","first-page":"503","article-title":"IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome","volume":"10","author":"Ahmed","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.vph.2015.03.014_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/01.RES.88.2.245","article-title":"Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin","volume":"88","author":"Pierangeli","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.vph.2015.03.014_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/1529-0131(200001)43:1<55::AID-ANR8>3.0.CO;2-M","article-title":"Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis","volume":"43","author":"Kaplanski","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vph.2015.03.014_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/art.38785","article-title":"Role of toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome","author":"Benhamou","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vph.2015.03.014_bb0040","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.2009.1346","article-title":"Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome","volume":"302","author":"Charakida","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2015.03.014_bb0045","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1742-1241.2004.00162.x","article-title":"Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome","volume":"58","author":"Mercanoglu","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.vph.2015.03.014_bb0050","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-08-2349","article-title":"Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies","volume":"101","author":"Raschi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.vph.2015.03.014_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1191\/0961203305lu2048oa","article-title":"Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies","volume":"14","author":"Forastiero","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.vph.2015.03.014_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.nbd.2007.12.004","article-title":"Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome","volume":"30","author":"Tanne","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.vph.2015.03.014_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/0961203307086931","article-title":"Antiphospholipid antibodies induce vascular functional changes in mice: a mechanism of vascular lesions in antiphospholipid syndrome?","volume":"17","author":"Belizna","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.vph.2015.03.014_bb0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4049\/jimmunol.174.1.485","article-title":"TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss","volume":"174","author":"Berman","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vph.2015.03.014_bb0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/03009740802363768","article-title":"Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients","volume":"38","author":"Sidiropoulos","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.vph.2015.03.014_bb0080","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1161\/01.CIR.0000037521.71373.44","article-title":"Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis","volume":"106","author":"H\u00fcrlimann","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.03.014_bb0085","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vph.2015.03.014_bb0090","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/01.CIR.99.15.1997","article-title":"Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo","volume":"99","author":"Pierangeli","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.03.014_bb0095","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00296-009-1314-8","article-title":"Increased level of tumor necrosis factor-\u03b1 in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state","volume":"31","author":"Swadzba","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.vph.2015.03.014_bb0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1160\/TH12-06-0421","article-title":"Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome","volume":"109","author":"Prinz","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.014_bb0105","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1161\/hc5001.101749","article-title":"Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure","volume":"104","author":"Fichtlscherer","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2015.03.014_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/01.RES.73.1.205","article-title":"Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life","volume":"73","author":"Yoshizumi","year":"1993","journal-title":"Circ Res"},{"key":"10.1016\/j.vph.2015.03.014_bb0115","first-page":"L51","article-title":"Superoxide responses of endothelial cells to C5a and TNF-alpha: divergent signal transduction pathways","volume":"263","author":"Murphy","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.vph.2015.03.014_bb0120","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2005.06.044","article-title":"Human monoclonal IgG anticardiolipin antibodies induce nitric oxide synthase expression","volume":"185","author":"Alves","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.vph.2015.03.014_bb0125","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/1529-0131(199812)41:12<2205::AID-ART16>3.0.CO;2-Q","article-title":"Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2)","volume":"41","author":"Perkins","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vph.2015.03.014_bb0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11010-009-0259-2","article-title":"TNF-alpha modulates iNOS expression in an experimental rat model of indomethacin-induced jejunoileitis","volume":"336","author":"Nandi","year":"2010","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.vph.2015.03.014_bb0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0891-5849(95)02026-8","article-title":"Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase","volume":"20","author":"Miesel","year":"1996","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.vph.2015.03.014_bb0140","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/HYPERTENSIONAHA.110.157685","article-title":"Tumor necrosis factor-\u03b1 antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus","volume":"56","author":"Venegas-Pont","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.vph.2015.03.014_bb0145","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10067-009-1325-6","article-title":"The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis","volume":"29","author":"Karkucak","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vph.2015.03.014_bb0150","first-page":"73","article-title":"Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis","volume":"26","author":"Kageyama","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.vph.2015.03.014_bb0155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0008-6363(99)00134-0","article-title":"Tetrahydrobiopterin and endothelial nitric oxide synthase activity","volume":"43","author":"Cosentino","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.vph.2015.03.014_bb0160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00005344-200002000-00001","article-title":"Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease","volume":"35","author":"Maier","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.vph.2015.03.014_bb0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11010-009-0184-4","article-title":"The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension","volume":"332","author":"Tran","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.vph.2015.03.014_bb0170","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.dld.2013.06.007","article-title":"Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice","volume":"45","author":"Lopetuso","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.vph.2015.03.014_bb0175","doi-asserted-by":"crossref","first-page":"G938","DOI":"10.1152\/ajpgi.00469.2007","article-title":"Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies","volume":"294","author":"Fries","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.vph.2015.03.014_bb0180","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1440-1843.2008.01278.x","article-title":"Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma","volume":"13","author":"Deveci","year":"2008","journal-title":"Respirology"},{"key":"10.1016\/j.vph.2015.03.014_bb0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1398-9995.2010.02476.x","article-title":"Anti-tumor necrosis factor-alpha treatment reduces allergic responses in an allergic rhinitis mouse model","volume":"66","author":"Mo","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.vph.2015.03.014_bb0190","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood.V89.2.541","article-title":"Monocytes upregulate endothelial cell expression of tissue factor: a role for cell\u2013cell contact and cross-talk","volume":"89","author":"Napoleone","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.vph.2015.03.014_bb0195","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1073\/pnas.83.12.4533","article-title":"Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1","volume":"83","author":"Bevilacqua","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vph.2015.03.014_bb0200","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/01.ATV.16.11.1319","article-title":"Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s","volume":"16","author":"Reverter","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.vph.2015.03.014_bb0205","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1055\/s-0037-1614881","article-title":"Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome","volume":"82","author":"Dobado-Berrios","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2015.03.014_bb0210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.intimp.2012.08.018","article-title":"Thromboembolic events and anti-tumor necrosis factor therapies","volume":"14","author":"Masson","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vph.2015.03.014_bb0215","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10067-013-2244-0","article-title":"Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature","volume":"32","author":"Hemmati","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vph.2015.03.014_bb0220","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1136\/ard.2011.153536","article-title":"Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Davies","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vph.2015.03.014_bb0225","first-page":"355","article-title":"Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000\u20132006","volume":"19","author":"Petitpain","year":"2009","journal-title":"Biomed Mater Eng"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189115000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T20:01:49Z","timestamp":1598904109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189115000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":45,"alternative-id":["S1537189115000592"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2015.03.014","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: Role of reduced oxidative stress","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2015.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}